SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Sharck Soup
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sharck who wrote (29286)6/23/2001 11:02:10 AM
From: aknahow  Read Replies (3) of 37746
 
As to who needs the approval more, think again. If you have earnings and miss the concensus by a few cents you have a real problem. If you have no sales or earnings only fools pay attention to quarterly earnings reports just for the "earning/loss" number. Approval for either drug is still a distant event. Until the final words from the FDA both stocks will move in part on which drug the market thinks will gain approval. XOMA has more things in the pipeline than most realize including potential new partnerships. The Baxter partnership is not well understood as much of it is still confidential. Clinical trials for crohn's begin sometime in July, if things go as XOMA has said.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News